ClinicalTrials.gg
Active, not recruitingNCT07160335Updated Oct 20, 2026

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

A Phase 1 interventional study of HLX17 and US-sourced Keytruda® in Non-small Cell Lung Cancer, Melanoma and Renal Cell Carcinoma, sponsored by Shanghai Henlius Biotech. Active, not recruiting at 69 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma — 11 open to participants now, 15 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Fosun Pharma.

Planned enrollment
7th of 17
174 · median 150
Started
2025
with 3 others
Phase 1
4 of 17
2 open now
Primary completion
2027-04
later than 8 of 14 live
Registered
12th of 17
by date

Among the 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma, this one is the 7th largest by planned enrollment, is one of 4 that started in 2025, is one of 4 in phase 1, reaches primary completion later than 8 of the 14 other live ones, and was the 12th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

11 of the 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma are open now, in 2 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Carcinoma, Non-Small-Cell Lung by Fosun Pharma, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17 vs. US-sourced Keytruda® in patients with resected non-small cell lung cancer (NSCLC) or melanoma (MEL), or renal cell carcinoma (RCC).

03

Conditions studied

  • Non-small Cell Lung Cancer
  • Melanoma
  • Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have signed and dated an Institutional Review Board/Independent Ethics Committee (IRB/IEC) approved written form (ICF) in accordance with regulatory and institutional guidelines.
  2. At least 18 years and no older than 85 years (including 85 years old) at the time of signing the ICF.
  3. 18 kg/m2 ≤ (BMI) ≤ 30 kg/m2 and 50 kg ≤ body weight ≤ 85 kg.
  4. The patient with one of the following resected solid tumors:

    • NSCLC patients after complete resection OR
    • Melanoma following complete resection OR
    • Renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of lesions.
  5. Have a performance status of 0 on the (ECOG) Performance Status within 7 days prior to the first dose in this study.
  6. Have a of at least 12 weeks.
  7. Have adequate organ function as indicated by the following laboratory values (no blood transfusions, or treatment with albumin, recombinant human thrombopoietin or colony-stimulating factor within 14 days prior to the first dose in this study)
  8. Female patients must meet one of the following conditions:

    1. Menopause (defined as no menstruation for at least 1 year with no confirmed cause other than menopause), or
    2. Surgically sterilized (removal of the ovaries and/or uterus), or
    3. Fertile, but must:

      • be tested negative for serum/urine pregnancy test within 7 days prior to the randomization, and
      • agree to use methods with an annual failure rate of \< 1% or to remain abstinent (avoid heterosexual intercourse from signing the ICF to at least 6 months after the last dose of the study drug) (a contraceptive method with an annual failure rate of \< 1% includes bilateral tubal ligation, male sterilization, correct use of hormonal contraceptives that can inhibit ovulation, hormone-releasing intrauterine devices and copper-containing intrauterine devices or condoms), and
      • not breastfeed
  9. Male patients must: agree to remain abstinent (avoid heterosexual intercourse) or take contraception measures as follows: male patients with a pregnant partner or a partner of must remain abstinent or use condoms to prevent drug exposure to the embryo during study treatment and for at least 6 months after the last dose of study drug. Periodic abstinence (e.g., contraception based on calendar day, ovulatory phase, basal body temperature, or postovulatory phase) and external ejaculation are ineligible methods of contraception.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women.
  2. History of illicit drug use or alcohol abuse within 12 months prior to randomization in the investigator's judgment.
  3. Participants with NSCLC have two synchronous primary non-small cell lung cancers or other histopathological types (such as mixed adenosquamous carcinoma, small cell lung cancer, or neuroendocrine carcinoma); known positive for EGFR sensitive mutations or ALK fusion. EGFR sensitive mutations include: exon 19 deletion mutation (19DEL) and exon 21 point mutation (21L858R).
  4. Participants with MEL have mucosal or ocular melanoma.
  5. Participants with RCC have pre-existing brain or bone lesions, or residual thrombus in the renal vein or vena cava after nephrectomy.
  6. Participants with other primary active within 5 years or at the same time prior to randomization.
  7. Have received an organ or bone marrow transplantation prior to randomization or scheduled for transplantation during the study.
  8. Presence of central nervous system (CNS) metastases and/or carcinomatous meningitis.
  9. Symptomatic cerebrovascular disease or known myocardial infarction or poorly controlled arrhythmia (including intervals ≥ 450 ms for males and ≥ 470 ms for females calculated by Fridericia's formula) within 6 months prior to randomization.
  10. Chronic heart failure (Class III to IV based on classification) or an (left ventricular ejection fraction) assessed with the doppler echocardiography less than 50%.
  11. Peripheral neuropathy greater than or equal to Grade 2 ().
  12. Known (HIV) infection (or positive anti-HIV during screening), or known (or positive test for HBsAg or HBcAb and positive test for HBV-DNA during screening), or known (or positive tests for HCV antibody and HCV-RNA during screening), or known Hepatitis B and C co-infection (or positive test for HBsAg or HBcAb and positive test for HCV antibody during screening), or active pulmonary tuberculosis within 6 months prior to randomization.
  13. Known interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, and severe lung function abnormalities that may impede the investigators' diagnosis and management of drug-related pulmonary toxicity prior to screening.
  14. Known severe allergic or anaphylactic reactions to pembrolizumab or any other monoclonal antibody or any components of the medicinal products.
  15. Known active or suspected diseases. Patients with stable disease who do not require systemic therapy may also participate.
  16. Unstable hyperthyroidism or hypothyroidism at screening.
  17. Have received within 28 days prior to the first dose in this study (Inactivated viral vaccines for seasonal influenza are allowed).
  18. Treatment with systemic (> 10 mg/day prednisone efficacy dosage) or other immunosuppressive drugs within 14 days prior to the first dose or during the study. However, participants are allowed to be enrolled under the following conditions: in the absence of active autoimmune disease, participants are allowed to use topical or inhaled steroids and adrenal hormone replacement therapy at dosages equivalent to ≤ 10 mg/day of prednisone efficacy.
  19. Any active infection requiring systemic therapy within 1 month prior to the first dose in this study.
  20. Participants have planning to undergo surgical treatment during this clinical trial. Tumor puncture or incisional lymph node is allowed.
  21. Have received pembrolizumab or any other immune checkpoints inhibitors (, PD-L1, CTLA4, etc.) before randomization.
  22. Participants have participated in a clinical study with another investigational medicinal product prior to randomization, and the interval between the current study and the previous study is too short: within 1 month prior to the first dose of the current study or within 5 half-lives of the previous investigational medicinal product (whichever is longer). Or planning to participate in a clinical study with another investigational medicinal product before completing all scheduled assessments in this clinical study.
  23. Participants have participated in a device clinical study within 1 month prior to screening, or are participating in another surgical or device clinical study at the time of screening, or plan to participate in another surgical or device clinical study during this clinical study.
  24. The investigator has a clear reason to believe that participation in this study would be detrimental to the participant.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    HLX17

    Subjects will receive HLX17 (200 mg) on Day 1 of each 3-week cycle, until 12 months after the randomization (nearly 17 cycles) or investigator-assessed disease recurrence, death, initiation of new anti-tumor therapy, unacceptable drug toxicity, withdrawal of informed consent form, or study termination (whichever occurs first).

    Drug: HLX17

  • Active comparator
    US-sourced Keytruda®

    Subjects will receive US-sourced Keytruda® (200 mg) on Day 1 of each 3-week cycle, for a total of 8 cycles (24 weeks). After 8 cycles, all subjects in the US-sourced Keytruda® group will receive HLX17 200 mg on Day 1 of each 3-week cycle until 12 months after the randomization (nearly 17 cycles) or investigator-assessed disease recurrence, death, initiation of new anti-tumor therapy, unacceptable drug toxicity, withdrawal of informed consent form, or study termination (whichever occurs first).

    Drug: HLX17 · Drug: US-sourced Keytruda®

Interventions

  • DrugHLX17

    Subjects will receive HLX17 (200 mg) on Day 1 of each 3-week cycle

    Also known as: pembrolizumab

  • Subjects will receive US-sourced Keytruda® (200 mg) on Day 1 of each 3-week cycle

    Also known as: pembrolizumab

06

What researchers measure

Primary outcomes

  1. AUC0-21d

    Area under the serum concentration-time curve from time 0 to 21 days (AUC0-21d) after the 1st dose

    Time frame: rom time 0 to 21 days after the 1st dose (3 weeks)

  2. AUCss

    Area under the serum concentration-time curve within a dosing interval at steady state (AUCss) after the 6th dose

    Time frame: from time 0 to 21 days after the 6th dose (18 weeks)

Secondary outcomes

  1. maximum serum drug concentration (Cmax),

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: up to 24 weeks

  2. trough serum drug concentration at steady state (Ctrough,ss)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: up to 24 weeks

  3. maximum serum drug concentration at steady state (Cmax,ss)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: up to 24 weeks

  4. trough serum drug concentration (Ctrough)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: up to 24 weeks

  5. DFS

    Defined as the time from randomization to tumor recurrence, the development of new tumor lesions, or death due to any reasons (whichever occur first).

    Time frame: up to 12 months

  6. Adverse events

    Adverse events (AEs) Serious adverse events (SAEs) Adverse events of special interest (AESIs) (including immune-related adverse events and infusion-related reactions)

    Time frame: From enrollment to the end of 90-day safety follow-up (up to 15 months)

  7. Number of participants with abnormal vital signs

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: From enrollment to the end of 30-day safety follow-up (up to 13 months)

  8. Number of participants with abnormal physical examination findings

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: From enrollment to the end of 30-day safety follow-up (up to 13 months)

  9. Number of participants with abnormal Laboratory tests results (hematology, serum chemistry, thyroid function, coagulation function, and myocardial markers)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: From enrollment to the end of 30-day safety follow-up (up to 13 months)

  10. Number of participants with abnormal 12-lead ECG readings

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: From enrollment to the end of 30-day safety follow-up (up to 13 months)

  11. Immunogenicity endpoint

    Incidence of anti-drug antibody (ADA) and/or neutralizing antibody (NAb)

    Time frame: up to 24 weeks

07

Study locations

69 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Apr 2027, 19 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 19 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Sep 8, 2025
StartActual
Sep 26, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Mar 27, 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07160335
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Sep 26, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Mar 27, 2028 (estimated)
Last update
Oct 20, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion